• BSE
  • NSE
    • {{d.cmpname}}
    • {{d.price}}
    • ({{d.PerChg}}%)
Equity | News | Hot Pursuit
Hot Pursuit
Torrent Pharma Q2 profit rises 30% YoY
Back
(16:48, 08 Nov 2025)
On a consolidated basis, its revenue rose 14% year-on-year to Rs 3,302 crore, compared to Rs 2,889 crore in Q2 FY25, supported by double-digit growth across major geographies. Gross profit stood at Rs 2,502 crore, up 13% YoY, maintaining a healthy margin of 76%.

Operating EBITDA increased 15% YoY to Rs 1,083 crore, with the margin steady at 33%. Profit after tax (PAT) surged 30% YoY to Rs 591 crore, translating to a net margin of 18% compared with 16% in the year-ago quarter. R&D spend for the quarter stood at Rs 156 crore, up 8% year-on-year, accounting for 5% of revenues.

The company reported an exceptional item of Rs 13 crore, related to regulatory and statutory filing fees for acquiring a controlling stake in J.B. Chemicals & Pharmaceuticals.

On the geography front, India revenues grew 12% YoY to Rs 1,820 crore, outperforming the Indian Pharmaceutical Market (IPM) growth of 8%, led by strong traction in chronic therapies and successful new launches. Torrent's chronic segment grew 13% vs IPM's 11%, and 21 of its brands now feature among the top 500 in India.

Brazil business rose 21% YoY to Rs 318 crore, driven by strong brand performance and new product launches, while U.S. revenues surged 26% YoY to Rs 337 crore on the back of recent launches that achieved targeted market share. Germany revenues grew 5% to Rs 303 crore, although supply disruptions at a third-party supplier affected constant currency growth, which declined 5% YoY.

Torrent Pharma is the flagship Company of the Torrent Group. It is ranked 7th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved.

Shares of Torrent Pharmaceuticals rose 0.70% to settle at Rs 3579.50 on 7 November 2025.

Powered by Capital Market - Live News

Top
Scores
Scores 2.O
Online Dispute Redressal (ODR)
Investor Charter
Invester Complaint
Advisory for Investors
Liquidity Enhancement Scheme
KYC documents in vernacular languages
KYC documents in vernacular languages of commodities
.
Stock Broker Name Registration Number Registered Address Branch Address Contact Number Email id
DB (International) Stock Brokers Limited INZ000179035 (BROKING)

IN-DP-CDSL-266-2004 (DEPOSITORY) 		Unit No. 210/211/211A at 2nd floor, Dalal Street Commercial Cooperative Society Ltd, Block No.53, Zone 5, Gift City, Gandhinagar, Gujarat-382355 Head Office – 114, New Delhi House, 27 Barakhamba Road, Delhi 110001 011-43606162 compliance@dbonline.in
51, Mini Market T/F Mandir Wali Gali, Yusaf Sarai, New Delhi 110016 011-35936102 greenpark@dbonline.in
C-12, DB Plaza, RDC Raj Nagar, Ghaziabad 201002 0120-4150393 ghaziabad@dbonline.in
Plot No 4, Wasme House, Film City Sector 16A, Noida – 201301 0120-4823200 compliance@dbonline.in
Out Side Jassusar Gate, Bikaner, Rajasthan – 334001 9001643408 bikaner@dbonline.in
Office No 101, City Center, Opp. High Court, M G Road, Indore 452001 9424083019 brajeshsadani@dbonline.in
203, Marshal House 25, Strand Road, Kolkata 700001 033-40055270 b032@dbonline.in
Shop No.-7, 2nd Floor, Amar Complex, Opp. Hanumaan Mandir, The Mall, Solan- 173212 6230604596 parwanoo@dbonline.in
Daga Commodities Private Limited INZ000028833 114, New Delhi House, 27 Barakhamba Road, Delhi 110001- 0120-4823200 compliance@dbonline.in
Daga Business (International) Stock Brokers (IFSC) Private Limited INZ000202436 Unit No. 228, Signature Building, Second Floor, Block 13B, Zone-1, Gift SEZ, Gandhinagar, Gujarat 382355 - 0120-4823200 compliance@dbonline.in

Disclosure regarding proprietary trading:

As required under Circular No. SEBI/MRD/SE/Cir-42/2003 dated 19.11.2003 issued by the Securities and Exchange Board of India; We hereby disclose that in addition to client based business, We are also doing proprietary trading.

Investor Grievances Email ID: investorgrievance@dbonline.in


Copyright © 2016 All rights Reserved DB (International) Stock Brokers Ltd.     Designed, Developed and content powered by C-MOTS Infotech( ISO 9001:2015 certified )
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."         "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors."          "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Attention Investors ::
subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries | Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. | Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. | Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month........... Issued in the interest of Investors"